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Background: Statin therapy has been reported to increase myopathy rates. It is hypothesized that statin therapy in combination with interacting 
drugs may increase the rate of myopathy. It is further hypothesized that the myopathy rates may increase over time due to accumulated toxicity.
Methods: Medical records from Northwestern Medical Enterprise Data Warehouse over a 7-year period (from 2004 to 2010) are analyzed to study 
myopathy incidence rates for patients taking statin with concurrent medications. Patient data over the same period is also analyzed with several 
common comorbidities.
Results: In the study population the prevalence of myopathy is 0.52% (CI, 0.42-0.62) with statin mono therapy, and 1.50% (95% CI, 1.35-
1.64) with statin use in combination with other agents. Amiodarone and protease inhibitors presented the highest prevalence of myopathy (3.2% 
and 4.0%, respectively) compared to all patients receiving combination therapy (p < .001 and p = .045, respectively). In the population with 
comorbidities the prevalence of statin-related myopathy rates increase from 0.75% (monotherapy) to 2.12% (combination therapy) (p < .001). 
However, myopathy prevalence among patients on statin therapy has not changed during the seven year study period.
Conclusions: Patients on statin therapy should be monitored more closely when concurrently taking other medications and presenting additional 
comorbidities. Steady prevalence rate of myopathy may be attributed to greater care in prescribing statin therapy due to increased awareness.
